The investigation was spearheaded by a distinguished research team including Dr. Peter J. Gianaros, Director of the Center for Mind-Body Science and Health at the University of Pittsburgh, alongside Dr. Kirk I. Erickson of the AdventHealth Research Institute. The collaborative effort aimed to elucidate the mechanistic pathways through which the American Heart Association’s recommended 150 minutes per week of moderate-to-vigorous aerobic activity exerts protective effects on stress biology, emotional regulation, and cardiovascular risk factors.

Participants numbering 130 adults aged between 26 and 58 were meticulously randomized into two cohorts. The intervention group adhered to a moderate-to-vigorous aerobic exercise regimen spanning 150 minutes weekly, while the control group received health information but did not alter their physical activity patterns. Over the course of the year-long intervention, detailed biometric assessments—including cardiorespiratory fitness metrics, salivary and serum cortisol sampling, and advanced brain imaging modalities—provided comprehensive data on physiological and neurobiological adaptations.

One of the most salient findings from the trial was a statistically significant reduction in long-term cortisol levels among the exercise group. Cortisol, synthesized by the adrenal cortex, orchestrates myriad processes including metabolism, immune modulation, circadian rhythm, cognitive function, and mood stability. Importantly, dysregulation characterized by chronically elevated cortisol adversely affects cardiovascular health, metabolic equilibrium, and mental well-being. Thus, the observed cortisol attenuation suggests a molecular underpinning for how aerobic exercise might confer broad-spectrum health benefits.

Dr. Gianaros elaborated on these findings, hypothesizing that the modulation of basal cortisol levels could represent a critical biological mechanism through which physical activity mitigates disease risk and fortifies mental health resilience. However, he emphasized the necessity of further mechanistic studies to delineate causality, potential dose-response relationships, and the longevity of these neuroendocrine benefits beyond the intervention period.

Beyond the hormonal outcomes, the trial integrated state-of-the-art neuroimaging techniques including functional MRI and structural connectivity analyses, which revealed exercise-associated decelerations in brain aging trajectories. These observations reinforce the hypothesis that aerobic exercise exerts neuroprotective effects by engaging autonomic and central nervous system pathways that regulate stress and cognitive function, thereby potentially delaying neurodegenerative processes.

Cardiorespiratory fitness improvements were robust among exercisers, highlighting the interplay between enhanced physiological capacity and stress-buffering effects. Enhanced aerobic fitness is known to optimize autonomic balance, reduce sympathetic overactivity, and improve vascular endothelial function, all of which are implicated in reduced cardiovascular morbidity and improved psychological health.

The study also sheds light on the intricate relationship between stress biology and socio-emotional well-being, indicating that regular aerobic exercise may serve as a non-pharmacological strategy to alleviate affective disorders and enhance psychological resilience. By dampening stress hormone overexposure and fostering adaptive neural plasticity, physical activity emerges as a potent modulator of both brain and systemic health in midlife.

Crucially, this trial overcomes longstanding limitations of correlational research by employing a controlled experimental design over an extended timeline. This empowers clinicians and public health practitioners with robust evidence to advocate for adherence to physical activity guidelines as a cornerstone of both cardiovascular and mental health prevention strategies.

Funding for this innovative research was provided by the National Institutes of Health and the National Heart, Lung, and Blood Institute, underscoring the national significance of understanding exercise-induced stress modulation. The multidisciplinary approach, combining psychological science, neurobiology, endocrinology, and exercise physiology, sets a new standard for future investigations seeking to unravel complex mind-body interactions.

The findings by Dr. Gianaros, Dr. Erickson, and their team not only affirm the physiological importance of maintaining physical activity throughout adulthood but also illuminate novel biomarkers and neural circuits susceptible to lifestyle interventions. Ultimately, this groundbreaking work paves the way for precision medicine approaches targeting stress-related pathology through tailored exercise prescriptions.

Ongoing research building on these findings is anticipated to delve deeper into molecular signaling pathways, epigenetic modifications, and psychosocial mediators that collectively influence the stress-exercise nexus. Such knowledge is vital to optimize intervention timing, intensity, and modality to maximize therapeutic benefit for diverse populations at risk for stress-related disorders and cardiovascular disease.

This comprehensive clinical trial fundamentally reshapes our understanding of how sustained aerobic exercise confers resilience on neuroendocrine regulation of stress and brain aging, holding profound implications for improving quality of life and reducing the burden of chronic diseases in midlife and beyond.

Subject of Research: People

Article Title: Effects of a year-long aerobic exercise intervention on neuroendocrine, autonomic, and neural correlates of stress, emotion, and cardiovascular disease risk in midlife adults

News Publication Date: 17-Mar-2026

References: DOI: 10.1016/j.jshs.2026.101135

Image Credits: Dr. Peter J. Gianaros, University of Pittsburgh, USA; created with BioRender

Keywords: Health and medicine, Mental health, Stress management, Neuroscience, Cardiovascular disorders

This novel randomized controlled trial (RCT) aims to fill this critical knowledge gap by systematically investigating the effects of a supervised resistance exercise intervention on sarcopenia progression and related clinical outcomes in women undergoing neoadjuvant chemotherapy for breast cancer. Targeting a cohort of 46 female patients aged 20 and older, the study is uniquely positioned to unravel the complexities of muscle preservation within the context of aggressive cancer treatment modalities. Executed under robust methodological standards, this trial promises to enhance therapeutic strategies significantly, ultimately improving patients’ quality of life and treatment tolerance.

The rationale underpinning the trial is deeply rooted in the multifactorial impact of sarcopenia on cancer management. Patients exhibiting significant muscle wasting are known to experience increased susceptibility to chemotherapy-induced toxicities, prolonged hospitalization, and reduced functional independence. Furthermore, existing literature highlights that sarcopenia can aggravate cancer-related symptoms such as fatigue, pain, and diminished physical performance, which cumulatively impair psychological and social well-being. As such, interventions targeting sarcopenia are not merely supportive but integral to comprehensive oncological care pathways.

By implementing a hybrid, expert-supervised resistance exercise regimen, the research team addresses a critical barrier to intervention feasibility—patient accessibility. Recognizing that physical debilitation, treatment side effects, and geographic constraints often limit consistent participation, the program offers both on-site and virtual training sessions. Each participant will engage in three 60-minute resistance exercise sessions per week, empowering patients with flexibility while ensuring adherence to rigorous exercise protocols. This innovative delivery model is anticipated to foster higher retention rates and robust data collection.

Alongside tracking changes in muscle mass, the trial will employ a battery of validated assessments, measuring muscle strength and physical performance as core indicators of sarcopenia reversal or stabilization. These objective physiological markers are complemented by self-reported evaluations of cancer-related symptoms and overall quality of life. The multidimensional outcome framework underscores the study’s commitment to capturing the comprehensive impact of resistance exercise, encompassing not only physical but also psychosocial dimensions of patient health.

Importantly, this investigation integrates a longitudinal design with multiple assessment timepoints—baseline, mid-intervention at six and twelve weeks, and upon program completion at eighteen weeks. Such granularity allows for dynamic tracking of intervention effects and the identification of critical windows during chemotherapy when resistance training may yield maximal benefit. The resulting data will inform optimal exercise prescription parameters tailored to the breast cancer neoadjuvant setting.

This RCT is situated within the institutional support of Yonsei University Health System’s Severance Hospital, adhering to stringent ethical standards under institutional review board approval. The prospective registration of the trial (Clinical Research Information Service, reference KCT0008961) further emphasizes transparency and scientific rigor, facilitating replication and inclusion in future meta-analyses.

Beyond direct clinical outcomes, the study has broader implications for oncology rehabilitation frameworks. The integration of prehabilitation exercise protocols into standard cancer care pathways demands evidence-based validation, particularly for vulnerable populations experiencing sarcopenia. Positive findings from this examination could serve as a catalyst for widespread implementation of resistance training as a non-pharmacological adjunct, potentially transforming supportive care paradigms and enhancing survivorship trajectories.

Current gaps in existing research often stem from heterogeneous study designs, small sample sizes, or retrospective analyses limiting causal inference. This trial’s randomized controlled design and hybrid delivery model mark a significant advance, providing high-quality evidence that is both internally valid and pragmatically feasible for real-world application. Addressing the challenge of neoadjuvant chemotherapy-associated sarcopenia with a multidisciplinary, exercise oncology approach resonates with contemporary calls for integrative cancer care.

Moreover, the focus on breast cancer, a disease with high global incidence and substantial survivorship populations, underscores the study’s public health relevance. Muscle preservation strategies that mitigate chemotherapy side effects could decrease healthcare utilization, reduce treatment interruptions, and improve long-term functional independence, all of which impart meaningful cost-effectiveness benefits.

Emerging mechanistic research also supports the biological plausibility of exercise-mediated sarcopenia mitigation. Resistance training is known to stimulate muscle protein synthesis via activation of mTOR pathways, enhance mitochondrial function, and reduce systemic inflammation—processes often dysregulated in cancer cachexia and treatment-induced muscle atrophy. This trial’s outcomes may provide clinical corroboration of these molecular insights in a cancer-specific cohort.

In conclusion, this pioneering RCT holds promise to reshape how oncologists and rehabilitation specialists approach musculoskeletal health in breast cancer patients receiving neoadjuvant chemotherapy. By rigorously examining resistance exercise as a prehabilitative strategy, the study aims to develop actionable, evidence-based interventions that integrate seamlessly into multidisciplinary cancer treatment plans. The anticipated results will not only clarify the role of exercise in sarcopenia management but also inspire future research into personalized, holistic cancer care.

As the oncology community continues to prioritize survivorship and quality of life, such innovative trials are indispensable in guiding clinical practice evolution. This research embodies the confluence of exercise science, oncology, and patient-centered care, marking an exciting frontier in supportive cancer therapies. The scientific and medical worlds eagerly await the insights this trial will yield, potentially heralding a new standard of care wherein resistance training becomes a routine, indispensable component of breast cancer treatment.

With enrollment commencing shortly and follow-up assessments meticulously planned, this study represents a beacon of hope for patients, clinicians, and researchers alike. Its outcomes could materially shift our understanding of how targeted physical interventions can modulate cancer treatment trajectories, enhancing resilience and wellbeing amidst the challenges of neoadjuvant chemotherapy. Ultimately, this endeavor epitomizes the spirit of translational medicine—turning laboratory and physiological knowledge into impactful clinical interventions that improve lives.

Subject of Research: Effects of resistance exercise intervention on sarcopenia in patients undergoing neoadjuvant chemotherapy for breast cancer.

Article Title: Evaluating the effects of a resistance exercise intervention for sarcopenia in patients receiving neoadjuvant chemotherapy for breast cancer: study protocol for a randomized controlled trial

Article References:
Jang, M.K., Park, S., Jeon, J.Y. et al. Evaluating the effects of a resistance exercise intervention for sarcopenia in patients receiving neoadjuvant chemotherapy for breast cancer: study protocol for a randomized controlled trial. BMC Cancer 25, 1296 (2025). https://doi.org/10.1186/s12885-025-14721-9

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14721-9